Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT02077959 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

OTHER

Sponsor class

Stopped Pharmaceutical Companies decision

Conditions

Multiple Myeloma

Interventions

DRUG: lenalidomide
BIOLOGICAL: pidilizumab
OTHER: pharmacological study
OTHER: laboratory biomarker analysis

Sponsor

Ohio State University Comprehensive Cancer Center

Collaborators

[object Object]